newsfilter
← Latest News
GlobeNewswire·

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company